Effects of indomethacin on the vascular abnormalities of Bartter's syndrome. 1978

C J Richards, and A L Mark, and D E Van Orden, and G J Kaloyanides

We examined the hypothesis that the vascular abnormalities of Bartter's syndrome are due to excess production of prostaglandin. Balance studies and vascular reactivity studies were performed before and after indomethacin (200 mg/day) in a patient with well-documented Bartter's syndrome. During indomethacin, potassium balance became positive, serum potassium rose from 2.1--3 mEq/1 in the absence of potassium supplementation, plasma renin activity decreased from 55--3.2 ng/day and peripheral plasma PGA-like activity fell from 1460 +/- 220 to 456 +/- 71 pg/ml. Before indomethacin, forearm vasoconstrictor responses to brachial arterial infusions of angiotensin II, norepinephrine and to neurogenic reflex stimulation elicited by lower body suction were greatly depressed compared to those of normal subjects. During indomethacin these responses were restored to normal. The dose of intravenous angiotensin II required to increase diastolic blood pressure 20 mm Hg decreased from 160--30 ng/kg/min. These data support the hypothesis that the vascular insensitivity to exogenous angiotensin II, norepinephrine and to neurogenic reflex stimulation observed in this patient with Bartter's syndrome is due to excess prostaglandin. Moreover, stimulation of the renin-angiotensin-aldosterone system in this syndrome appears to be a compensatory adaptation to excess prostaglandin production.

UI MeSH Term Description Entries
D007213 Indomethacin A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES. Amuno,Indocid,Indocin,Indomet 140,Indometacin,Indomethacin Hydrochloride,Metindol,Osmosin
D008297 Male Males
D011188 Potassium An element in the alkali group of metals with an atomic symbol K, atomic number 19, and atomic weight 39.10. It is the chief cation in the intracellular fluid of muscle and other cells. Potassium ion is a strong electrolyte that plays a significant role in the regulation of fluid volume and maintenance of the WATER-ELECTROLYTE BALANCE.
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D006439 Hemodynamics The movement and the forces involved in the movement of the blood through the CARDIOVASCULAR SYSTEM. Hemodynamic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006929 Hyperaldosteronism A condition caused by the overproduction of ALDOSTERONE. It is characterized by sodium retention and potassium excretion with resultant HYPERTENSION and HYPOKALEMIA. Aldosteronism,Conn Syndrome,Conn's Syndrome,Primary Hyperaldosteronism,Conns Syndrome,Hyperaldosteronism, Primary,Syndrome, Conn,Syndrome, Conn's
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001477 Bartter Syndrome A group of disorders caused by defective salt reabsorption in the ascending LOOP OF HENLE. It is characterized by severe salt-wasting, HYPOKALEMIA; HYPERCALCIURIA; metabolic ALKALOSIS, and hyper-reninemic HYPERALDOSTERONISM without HYPERTENSION. There are several subtypes including ones due to mutations in the renal specific SODIUM-POTASSIUM-CHLORIDE SYMPORTERS. Aldosteronism with Hyperplasia of the Adrenal Cortex,Bartter Disease,Bartter's Disease,Bartter's Syndrome,Juxtaglomerular Hyperplasia with Secondary Aldosteronism,Bartters Disease,Bartters Syndrome,Syndrome, Bartter,Syndrome, Bartter's
D012964 Sodium A member of the alkali group of metals. It has the atomic symbol Na, atomic number 11, and atomic weight 23. Sodium Ion Level,Sodium-23,Ion Level, Sodium,Level, Sodium Ion,Sodium 23

Related Publications

C J Richards, and A L Mark, and D E Van Orden, and G J Kaloyanides
December 1976, Lancet (London, England),
C J Richards, and A L Mark, and D E Van Orden, and G J Kaloyanides
June 1978, Revista clinica espanola,
C J Richards, and A L Mark, and D E Van Orden, and G J Kaloyanides
January 1979, La Nouvelle presse medicale,
C J Richards, and A L Mark, and D E Van Orden, and G J Kaloyanides
October 1980, The Journal of clinical endocrinology and metabolism,
C J Richards, and A L Mark, and D E Van Orden, and G J Kaloyanides
March 1980, American journal of diseases of children (1960),
C J Richards, and A L Mark, and D E Van Orden, and G J Kaloyanides
November 1984, Presse medicale (Paris, France : 1983),
C J Richards, and A L Mark, and D E Van Orden, and G J Kaloyanides
October 1976, Lancet (London, England),
C J Richards, and A L Mark, and D E Van Orden, and G J Kaloyanides
November 1982, Acta paediatrica Scandinavica,
C J Richards, and A L Mark, and D E Van Orden, and G J Kaloyanides
April 1978, The New England journal of medicine,
C J Richards, and A L Mark, and D E Van Orden, and G J Kaloyanides
March 2009, Indian journal of pediatrics,
Copied contents to your clipboard!